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Collagen-I and CCL8-CCR8 axis control the motility of ILC2 cells in the inflamed lung 19 
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Abstract 37 
Group 2 innate lymphoid cells (ILC2s) are enriched in mucosal tissues (e.g. lung) and respond 38 
to epithelial cell-derived cytokines initiating type-2 inflammation. During inflammation, ILC2 39 
numbers are increased in the lung. However, the mechanisms controlling ILC2 trafficking and 40 
motility within inflamed lungs remain unclear and are crucial for understanding ILC2 function 41 
in pulmonary immunity. Using several approaches, including lung intravital microscopy, we 42 
demonstrate that pulmonary ILC2s are highly-dynamic, exhibit amoeboid-like movement and 43 
aggregate in the lung peribronchial and perivascular spaces. They express distinct chemokine 44 
receptors, including CCR8, and actively home to CCL8 deposits located around the airway 45 
epithelium. Within lung tissue, ILC2s were particularly motile in extracellular matrix-enriched 46 
regions. We show that collagen-I drives ILC2 to dramatically change their morphology by 47 
remodeling their actin cytoskeleton to promote environmental exploration critical for regulating 48 
eosinophilic inflammation. Our study provides previously unappreciated insights into ILC2-49 
migratory patterns during inflammation and highlights the importance of environmental 50 
guidance cues in the lung in controlling ILC2 dynamics. 51 
 52 
 53 
  54 
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Introduction 55 
Innate lymphoid cells (ILC), are an emerging family of immune cells that originate from fetal 56 
liver and adult bone marrow (BM) progenitors (1, 2). Prenatally, ILC progenitors occupy 57 
peripheral sites from mid to late stages of fetal development (3), and are detectable in 58 
peripheral tissues by embryonic (E) day 15.5 in the mouse (4). Although ILC derive from 59 
common lymphoid progenitors, they lack specific antigen receptors and lymphoid cell lineage 60 
markers, but display diverse effector functions, analogous to T cells (5, 6). Based on distinct 61 
lineage-determining transcription factors, ILC segregate into three different subsets – ILC1, 62 
ILC2 and ILC3 (7-9). Each ILC subset mirrors a T helper cell subset via the production of T 63 
helper cell signature cytokines- IFN-γ (Th1/ILC1), IL-13 (Th2/ILC2) and IL-17 (Th17/ILC3) 64 
which act to combat infection by intracellular pathogens, helminths, and extracellular 65 
pathogens respectively (3). Anatomically, different ILC subsets are resident in particular 66 
barrier and non-barrier sites (3), including the BM, skin, secondary lymphoid organs, 67 
peripheral blood and non-lymphoid tissues. ILC3 are vital for the development of adaptive 68 
immune organs in utero, however after birth thymic ILC3 are replaced by ILC2 suggesting that 69 
these cells play an important role in the thymic microenivronment (10). Among non-lymphoid 70 
tissues, ILC2 are enriched in mucosal sites including the lung and small intestine, where they 71 
contribute to local tissue immunoregulation, repair and homeostasis (11, 12). In the mouse 72 
lung, ILC2 predominate (13), and rapidly expand during the first week of life (14, 15), 73 
populating collagen-rich structures associated with medium-sized blood vessels and airways 74 
(14). In a steady state, long term maintenance of ILC2 in peripheral tissues, including the lung, 75 
is mainly supported by self-renewal of proliferative local tissue resident progenitor populations 76 
(4, 15-18). Recent evidence suggests that ICAM-1 supports ILC2 development and function 77 
during lung inflammation (19). However, in T helper type-2 (Th2) cell induced lung 78 
inflammation, ILC2 exit the BM (19, 20) and concurrently numbers are increased in the blood 79 
and lung (21-24). Human and mouse ILC2 express 2 integrins and these have been 80 
proposed to be involved in cell trafficking since blocking 2 integrins results in reduced ILC2 81 
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numbers in the lung following allergen challenge (22). In addition, recent studies have 82 
identified a distinct pre-ILC2 population originating in the gut that migrates to the lung and 83 
other distal sites giving rise to inflammatory ILC2 (iILC2) that provide protection during worm 84 
infection (15). Within the lung, interaction of ILC2 with other immune cell populations is a 85 
critical factor for shaping type 2 inflammation (25). 86 
 87 
Several factors, including the epithelial cell-derived cytokines IL-33, IL-25 and thymic stromal 88 
lymphopoietin (TSLP), contribute to ILC2 activation and function (26). Upon activation, ILC2 89 
produce cytokines, including IL-4, IL-5, IL-13, colony stimulating factor 2 (CSF2; GM-CSF), 90 
and the epidermal growth factor family member amphiregulin (Areg) (13, 27-29). Lipid 91 
mediators, including the arachidonic acid metabolites leukotriene D4 (LTD4), prostaglandin D2 92 
(PGD2) (30, 31) and sphingosine 1-phosphate (S1P) (15) serve as potent regulators of ILC2 93 
activation, accumulation and function. In contrast PGE2 and PGI2 supress ILC2 function, 94 
inhibiting GATA-3, IL-5 and IL-13 expression and decreasing proliferation (32, 33). We have 95 
previously demonstrated that epithelial cell-derived transforming growth factor (TGF)-β1 is 96 
critical for ILC2 activation and significantly enhances airway ILC2 chemoactivity and 97 
movement in vitro (34). Thus, ILC2 activation, behaviour and function are regulated by a wide 98 
variety of factors.  99 
 100 
Tissue environments critically control optimal immune responses, coordinating timely and 101 
proportionate recruitment, motility, migration, chemotaxis, positioning, and cell–cell interaction 102 
of leukocytes within inflamed tissues (35). Factors, including lipids, cytokines and homing 103 
receptors (HRs) incorporating chemokine receptors (3) controlling migratory patterns of ILC2 104 
in the bone marrow (BM), spleen, gut, mesenteric lymph nodes (36) and skin (37, 38) have 105 
been identified. Lung ILC2 express high levels of β1 and β2 integrins, and use β2 integrins 106 
selectively to migrate from the BM to the lung after intranasal (i.n.) allergen (Alternaria 107 
alternata) challenge (39). Organ specific imprinting confers differential gene expression 108 
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patterns on tissue resident pulmonary ILC2 (40). However, ILC2 motility within the lung during 109 
inflammation remains unstudied, and little is known regarding the signals that might regulate 110 
it. Studies investigating T cell motility in the lung have described a combination of cell-intrinsic 111 
signals and physical guidance cues coupled with biochemical signals provided by the 112 
microenvironment in driving cell movement (41). However, the environmental guidance 113 
signals controlling ILC2 dynamic behaviour in the lung remain poorly defined. Here using IL13-114 
eGFP mice (28), combined with several imaging approaches, including lung intravital 115 
microscopy, we have documented that ILC2 exhibit amoeboid-like movement in the 116 
peribronchial and perivascular space after IL-33 induced lung inflammation. We identified 117 
specific molecules that communicate between the inflamed pulmonary environment and ILC2, 118 
uncovering the major environmental factors from which ILC2 interpret locomotory cues within 119 
the lung.  120 
 121 
Results 122 
 123 
The number of ILC2 rapidly increases in the peribronchial / perivascular region after 124 
rIL-33 treatment.  125 
Under homeostatic conditions, ILC2 exist in relatively low numbers in the lung, but are rapidly 126 
enriched after recombinant IL-33 (rIL-33) or rIL-25 induced inflammation (20-24, 39), 127 
promoting tissue repair during inflammation and regulating immune homeostasis. In this 128 
respect, ILC2 are thought to occupy a specific niche in the lung in keeping with their putative 129 
role as tissue resident sentinel cells (14). However, whether this locational niche is shared 130 
with CD4+ T cells remains unknown. Using IL13-eGFP mice, we investigated ILC2 numbers 131 
in various sites in the lung both at homeostasis and after acute exposure to either the fungal 132 
allergen Alternaria alternata (Alt) or rIL-33. We first quantified GFP+CD45+ cells among live 133 
lymphocytes that were either lineage positive versus lineage negative cells (fig. S1A). 134 
ILC2 were further defined by pre-gating on live (determined using a fixable live dead 135 
dye), GFP+CD3-NKp46- cells that were lineage (TCRβ, TCRγδ, CD5, CD19, CD11b, 136 
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CD11c, FCεR1, GR-1, F4/80, and TER-119) negative cells and co-expressed CD90.2, 137 
KLRG-1, CD127 and intracellular cytokine IL-13 (fig. S1B). As expected, in control mice, 138 
ILC2 were present in very low numbers in the airways, lung tissue and lung draining lymph 139 
nodes (mediastinal lymph node) (Fig. 1, A to C) as well as the blood, bone marrow, spleen, 140 
inguinal and mesenteric lymph nodes (fig. S2). However, during inflammation induced by i.n. 141 
administration of rIL-33 or Alt, ILC2 numbers significantly increased in the bronchoalveolar 142 
lavage fluid BAL (Fig. 1A), lung tissue (Fig. 1B) and the lung draining lymph nodes (Fig. 1C) 143 
as well as after rIL-33 treatment in the blood and bone marrow but not spleen, inguinal and 144 
mesenteric lymph nodes (fig. S2). To confirm that we were not excluding unstimulated ILC2 145 
(IL-13-/GFP-) in our gating, we additionally re-evaluated ILC2 numbers by gating on CD45+lin-146 
NKp46-CD3- cells and analysed the frequency of GATA-3+ (a faithful transcription factor to 147 
define all ILC2s) cells (fig. S3A). Here we used balb/c mice instead of IL-13 eGFP mice as the 148 
GFP signal was significantly lost following intra-nuclear staining for GATA-3. Balb/c mice were 149 
challenged with PBS, Alt or rIL-33 and lungs, BAL and blood ILC2s were evaluated by gating 150 
on GATA-3+ ILC2s. Our data suggests that ILC2s in mock treated mice are still very low in 151 
frequency compared to Alt and rIL-33 treatment (fig. S3B and C) and expressed significantly 152 
lower IL-13 and IL-5 (fig. S3D). Furthermore, by phenotyping GATA-3+ ILC2s for extracellular 153 
markers, our data suggests that each of the surface markers is altered as per the type of 154 
treatment as shown by the percent expression of each marker (fig. S3E-H) further highlighting 155 
the plasticity of ILC2s in inflammation.  156 
 157 
Similarly, imaging precision cut lung slices (PCLS) from rIL-33 treated IL13-eGFP mice, 158 
revealed substantialy more IL-13+GFP+ cells (fig. S4A) which largely accumulated around 159 
large airways and large blood vessels and to a lesser extent around alveolar capillaries (fig. 160 
S4B). To establish that the IL-13+GFP+ cells observed after rIL-33 treatment were pre-161 
dominantly ILC2, we evaluated the proportion of GFP+ cells that were CD45+linnegCD4- and 162 
expressed ILC2 defining markers (CD90.2, CD127, KLRG1,CD25 and co-expressed 163 
intracellular IL-13). Our data showed that 98.86% of observed GFP+ cells were ILC2, and only 164 
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1.14% of GFP+ cells were CD4 T cells (fig. S4C). The source of IL-13 by ILC2 versus CD4+ T 165 
cells after 1 week of rIL-33 administration was further quantified (fig. S4D).  166 
Since a minor proportion of CD4+ T cells produced IL-13 in our lung inflammation model, we 167 
included a CD4-T cell antibody to precisely evaluate the effects of rIL-33 administration on 168 
numbers and phenotype of CD4-GFP+ ILC2 in PCLS studies. Our PCLS imaging revealed that 169 
rIL-33 treatment induced a significant increase in GFP+ ILC2 numbers compared to Alt or mock 170 
treated mice (Fig. 1D). rIL-33 treatment induced a 6-fold greater ILC2 number compared to Alt 171 
treatment (Fig. 1,D and E), consistent with the number of ILC2 detected by flow cytometry 172 
(Fig. 1, A to C) and with a shared locational distribution in the inflamed lung tissue (fig. S4A). 173 
Interestingly GFP+ cells surrounding the bronchioles were significantly greater than the GFP+ 174 
cells in the alveolar tissue (fig. S4B). The majority of the GFP+ cells were IL-13 producing ILC2 175 
(fig. S4, C and D) and hence represented IL-13+ activated ILC2, referred from here on as ILC2 176 
for simplicity. Higher magnification views of the peribronchial space bordering the airways 177 
revealed an intimate association of some ILC2 with the airway epithelium and that ILC2 shared 178 
a locational niche with CD4+ T cells (Fig. 1F, depicting two representative images from a lung 179 
slice). Overall, we demonstrate that rIL-33 treatment significantly increased the number of lung 180 
ILC2 compared to Alt or PBS treatment and ILC2 accumulate around the airways of inflamed 181 
lungs.  182 
 183 
IL-33 stimulation induces ILC2 motility around blood vessels and airways.  184 
Intranasal administration of either rIL-33 or Alt induces robust inflammation in the lung (42, 185 
43). A hallmark of acute tissue inflammation is leukocyte recruitment. ILC2 are relatively rare 186 
in the lung compared to other leukocytes under homeostatic conditions but accumulate rapidly 187 
after rIL-33 induced inflammation (Fig. 1). We have previously demonstrated that the epithelial 188 
cell derived TGF-β induced after rIL-33 treatment promoted a high degree of ILC2 motility in 189 
vitro (34).  190 
 191 
9 
 
However, to date, dynamic movement of ILC2 has not been visualized in the lung. Since lung 192 
ILC2 are relatively rare at homeostasis (Fig. 1, B, D and E, fig. S3), we evaluated ILC2 193 
movement in the inflamed lungs of IL13-eGFP mice. Imaging live PCLS from rIL-33 treated 194 
IL13-eGFP mice showed that ILC2 were motile in the peribronchial and perivascular space 195 
(Fig. 2A; movie S1). Closer examination of the lung tissue surrounding the blood vessel 196 
revealed that the majority of ILC2 exhibited ‘amoeboid-like’ exploratory movement (Fig. 2, B 197 
and C; movies S2 and S3A) with pseudopodia and bleb-like processes in the extravascular 198 
lung tissue surrounding the blood vessel, while a lesser proportion of ILC2 exhibited 199 
‘oscillatory’ blebbing activity with little actual movement away from their start position (Fig. 2, 200 
B and C; movies S2 and S3B). Similar to oscillatory ILC2, CD4+ T cells (cyan) did not appear 201 
to displace from their point of origin in the lung tissue (Fig. 2B; movie S2). Cell tracking of ILC2 202 
and CD4+ T cells (Fig. 2, D and E) revealed that in PCLS from rIL-33-treated mice, ILC2 track 203 
speed (Fig. 2F), track length (Fig. 2G) and track displacement (Fig. 2H) was significantly 204 
higher than that of CD4+ T cells. Interestingly, ILC2 from Alt treated mouse lungs moved more 205 
slowly, with shorter tracks, compared to rIL-33-treated mice (Fig. 3, A and B). In addition, rIL-206 
33 treatment induced increased ILC2 track speed (Fig. 3C), track length (Fig. 3D) and track 207 
displacement (Fig. 3 E) compared to Alt treatment. Since rIL33 promoted greater ILC2 208 
movement than Alt treatment, we focused on rIL-33 induced changes on ILC2 motility 209 
thereafter. Since PCLS do not recapitulate the forces exerted by blood-flow and breathing in 210 
vivo, we also performed lung intravital microscopy in live mice using a similar strategy to 211 
previous work (44). We found that consistent with our data in live PCLS (Fig. 1, D to F, Fig. 2, 212 
A and B), ILC2 were enriched in the extravascular tissue close to larger blood vessels and 213 
exhibited amoeboid-like movement within the lung tissue (Fig. 3F, movie S4A and 4B).  214 
 215 
In summary, our results demonstrate that ILC2s are highly dynamic in the lung after treatment 216 
with either rIL-33 or allergen, where they exhibit amoeboid-like movement and travel faster 217 
over greater distances than CD4+ T cells.  218 
 219 
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ILC2s utilize distinct chemotactic pathways to home to inflammatory sites in the lung. 220 
We have shown that within the lung, ILC2s display a specific distribution pattern and 221 
movement behaviour distinct from T cells. However, the factors that regulate ILC2 dynamics 222 
are not well understood. Since ILC subsets have key features analogous to T cell populations, 223 
it has been suggested that molecular pathways which control motility, migration and tissue 224 
homing are common to ILC subsets and T cells, but this has not yet been proven. Therefore, 225 
we examined the pattern of chemokine receptor expression on ILC populations (defined as 226 
CD45+GFP+LinnegKLRG1+CD127+CD25var) isolated from the lungs of rIL-33 treated mice (or 227 
PBS treated controls) (fig. S5A and B). Surprisingly, despite the high degree of resemblance 228 
between ILCs and T cells, many of the prototypic chemokine receptors found on T cell subsets 229 
were absent on ILC, including CCR3, CCR4 (Th2), CCR6 (Th17), and CCR5 and CXCR3 230 
(Th1). Notably, ILC did express both CCR1 and CCR8, which are associated with type 2 231 
cytokine production by T cells in allergic contexts (45).   232 
 233 
Therefore, we examined expression of CCR1, 4 and 8 specifically on IL-13+ ILC2, finding that 234 
the majority of IL-13+ ILC2 express CCR1 (>50%) and/or CCR8 (>90%) and that the 235 
expression of these chemokine receptors was higher in rIL-33 treated mice than in PBS 236 
treated controls (Fig. 4A). In contrast to T cells, we found that CCR4 expression was not 237 
associated with a type 2 phenotype in ILC with only 10% of IL-13+ ILC also expressing CCR4. 238 
Furthermore, in vivo activation of ILC2 with rIL-33 did not alter CCR4 expression (Fig. 4A). 239 
Interestingly, we also found significantly greater levels of CCL8 protein, a ligand for CCR8 in 240 
mice (46) in the airways (Fig. 4B) and lungs (Fig. 4C) of rIL-33 treated mice compared to PBS 241 
treated control mice. We additionally evaluated other CCR8 ligands (CCL1) and CCR1 ligands 242 
(RANTES) (fig. S5C and D) in lungs of mice exposed to rIL-33 compared to control treated 243 
mice. PCLS and intravital imaging demonstrated that ILC2 accumulate in the peribronchial 244 
and perivascular space and are highly motile in rIL-33 treated IL13-eGFP mice (Fig. 2, A to C 245 
and Fig. 3F). Hence, we determined whether we could identify CCL8 chemokine deposits in 246 
areas of ILC2 movement in live PCLS of rIL-33 treated IL13-eGFP mice. CCL8 was strongly 247 
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expressed in the peribronchial space where ILC2 accumulate after rIL-33 treatment, at 248 
significantly greater levels than basal CCL8 expression in control mice (Fig. 4, D and E) with 249 
airway macrophages being the major producer for CCL8 in our model (fig. S5E).  250 
 251 
To examine the migration of ILC2 to chemotactic agents we sorted human ILC2 from 252 
peripheral blood (CD45+, Linneg, CD161+, CD127+, CRTH2+ and C-Kit variable-) then cultured with 253 
recombinant IL-2, IL-7 and IL-33 for at least 4 weeks (resulting in >99% ILC2). These ILC2s 254 
expressed GATA-3 and IL-13 (fig. S6A) and produced IL-13 (fig. S6B). Among the three 255 
cytokines required for ILC2 maintenance, our results suggest that IL-7 signalling in ILC2 was 256 
critical for their survival, proliferation and cytokine production as demonstrated by viability (fig. 257 
S6C) GATA-3 expression (fig. S6D), Ki67 staining (fig. S6E) and IL-5 production (fig. S6F). 258 
We additionally compared differences in motility between ILC2 starved of IL-2 vs IL-33 259 
compared to ILC2 that received all three cytokines. After 12h of live ex vivo imaging ILC2 track 260 
speed (fig. S6G) remained comparable (movie S5A, B and C). ILC2 that were starved of IL-7 261 
could not be included in this set up as absence of IL-7 significantly reduced ILC2 viability (fig. 262 
S6C). Our findings are consistent with the literature and reemphasize the importance of IL-7 263 
signalling being critical for the maintenance of ILC2 and other IL-7R+ lymphocyte populations 264 
(47). 265 
 266 
The potential of in vitro cultured ILC2 to migrate to a known ILC2 chemotactic factor - the 267 
eicosanoid PGD2 (48), was examined using a modified Boyden chamber chemotaxis assay 268 
(Fig. 4F). As expected, all human ILC2 lines tested migrated to PGD2 and peak chemotaxis 269 
occurred at a concentration of 100nM PGD2 consistent with previous studies (48). Since we 270 
found CCL8 in the BAL and CCL8 deposits in the lung of rIL-33 treated mice (Fig. 4, D and 271 
E), we queried whether CCL8 could induce the migration of human ILC2. Using the same 272 
modified Boyden chamber assay, we found that CCL8 also induced human ILC2 chemotaxis 273 
in a dose-dependent manner, peaking at 10nM CCL8 (Fig. 4G). We next compared migration 274 
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of ILC2 to factors thought to influence ILC2 movement. After determining the optimum 275 
concentrations for each factor, we found that although PGD2 was the most efficacious inducer 276 
of ILC2 migration, TGF-, IL-33 and CCL8 all promoted comparable levels of migration (Fig. 277 
4H). Taken together, these data identify specific chemokine receptor expression in ILC2 and 278 
show the corresponding ligand availability in areas of ILC2 accumulation. In order to confirm 279 
that CCL8-CCR8 axis plays an important functional role in ILC2 migration in vivo, we 280 
administered a blocking antibody against CCR8 or isotype Ab as a control and simultaneously 281 
treated mice with rIL-33. Our live PCLS data showed that blocking CCR8 significantly reduced 282 
ILC2 accumulation in the peribronchial region compared to control mice (Fig. 4, I and J) and 283 
ILC2 migration was impaired after CCR8 receptor blocking (movie S6, A and B) with shorter 284 
tracks depicted as track overlay between treatments (Fig. 4K) and reduced track length (Fig. 285 
4L), track speed (Fig. 4M) and track displacement (Fig. 4N). Closer analysis of ILC2 from each 286 
of these treatments revealed that significantly less of the ILC2 in rIL-33 treated mice receiving 287 
the anti-CCR8 blocking antibody expressed IL-13+IL-5+ (Fig. 4O) and those cells that did 288 
express the type 2 cytokines had significantly less IL-13 and IL-5 as determined by the mean 289 
fluorescence intensity (MFI) (Fig. 4P-R). Overall, our data suggests that the CCL8/CCR8 290 
pathway plays an essential role in inducing ILC2 accumulation, activation and movement 291 
within the lung during rIL-33 induced inflammation.  292 
 293 
Extracellular matrix proteins, collagen-I, collagen-IV and fibronectin, promote 294 
increased ILC2 motility  295 
In addition to chemokines, structural guidance cues such as extra cellular matrix (ECM) 296 
proteins have been shown to facilitate movement of immune cells, including T cells (41). In 297 
chronically inflamed lung tissue, as observed during asthma, aberrant ECM expression from 298 
tissue-remodelling can further influence immune cell activation and survival, thereby altering 299 
inflammatory immune responses (49). Therefore, we next examined whether ECM proteins 300 
influenced ILC2 movement. Fibronectin, collagen-I, III (fibrillar collagens) and collagen-IV 301 
(basement membrane collagen) are located around large airways and blood vessels and are 302 
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altered during lung inflammation (50). Proteoglycans such as versican and tenascin C are 303 
changed during remodelling in various lung disorders, including asthma and chronic 304 
obstructive pulmonary disease (COPD) (51).  305 
Therefore, the influence of collagens-I, -III and -IV, fibronectin, and proteoglycans, versican 306 
and tenascin C, on ILC2 movement was examined in a simplified 2D cell migration assay.  307 
Human ILC2 were cultured on these substrates and cell movement tracked over 12h in vitro 308 
by using an automated live cell imaging system using culture media with or without heat-309 
inactivated fetal bovine serum (FBS) as controls. In contrast to serum-free media, collagen-I, 310 
fibronectin and collagen-IV significantly enhanced dynamics of ILC2, as shown in the cell 311 
tracks and speeds (Fig. 5, A to C, movie S7, A to E). As expected, FBS supplemented media 312 
significantly enhanced cell movement (Fig. 5, A to C and movie S7B). In contrast to collagen-313 
I, fibronectin and collagen-IV, which showed strong effects on ILC2 dynamics, collagen-III, 314 
versican and tenascin C showed minimal influence on ILC2 movement (fig. S7A). Collagen 315 
fibres also produce contrast in two-photon microscopy by generating a strong second 316 
harmonic signal in tissue. Second harmonic generation (SHG) imaging suggested that the 317 
area around bronchioles and associated vessels had a strong fibrillar collagen component in 318 
both IL33-treated and control PCLS (Fig. 5D).  We noticed a qualitative difference in the SHG 319 
signal with the collagen fibres in perivascular / peribroncheal areas of rIL-33 treated mice 320 
appearing ‘spikier’ than those in PBS treated control mice. Therefore, we analysed the 321 
geometry of the SHG images of fibrillar collagen in the perivascular / peribronchial area using 322 
a grey level co-occurrence matrix (GLCM) technique to quantify and compare the SHG signal 323 
(52, 53). Initially we plotted correlation versus comparison distance. This analysis compares 324 
the organisation of the extracellular matrix by considering how far it is possible to travel in a 325 
straight line away from a start point and observe the same intensity (grey level) between pairs 326 
of pixels.  Images containing features that are generally organised in long straight lines will 327 
therefore have higher levels of intensity correlation over longer comparison distances and 328 
images that display structures more randomly orientated will lose this correlation at shorter 329 
comparison distances producing decays with steeper slopes.  As can be seen from the data 330 
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(Fig. 5E) GLCM SHG analysis of the perivascular / peribronchial area from IL-33 treated mice 331 
gave steeper decays than the controls, indicating a more disordered arrangement of shorter 332 
fibres. We also plotted homogeneity versus comparison distance. This parameter considers 333 
the distribution of grey levels at different comparison distances across the image. Therefore, 334 
images that have a texture less consistent with long fibrillar structures will have steeper decays 335 
in homogeneity with comparison distance. These data (Fig. 5, D and E) also highlighted 336 
contrast between the two conditions.     337 
In addition to collagen, fibronectin expression was also evaluated by staining for fibronectin in 338 
live PCLS from PBS or rIL-33 treated mice. Our results showed that fibronectin expression is 339 
enriched in the peribronchial region of rIL-33 treated mice (Fig. 5F). Collectively, our data 340 
indicate that collagen-I, -IV and fibronectin influence ILC2 speed in vitro. Furthermore,  341 
collagen and fibronectin are modified in areas where ILC2 accumulate during rIL-33 induced 342 
inflammation.  343 
 344 
Collagen-I enhances ILC2 actin cytoskeletal remodelling and polarity 345 
ECM protein ‘tracks’ can define the path of motile cells through the tissue (54). We observed 346 
that ILC2 exhibited amoeboid-like movement after rIL-33 induced inflammation (Fig. 2 and 3 347 
F). Amoeboid cell movement involves induction of a simple polarized shape, dynamic 348 
pseudopod protrusion and retraction, flexible oscillatory shape changes, and rapid low-affinity 349 
crawling (55). Our results showed that ECM proteins collagen-I, fibronectin and collagen-IV 350 
promoted increased human ILC2 motility in a 2D migration assay. Therefore, we next tested 351 
whether each ECM protein directly influenced changes in ILC2 phenotype, cytokine production 352 
and shape change in the same 2D environment. We found that ILC2 GATA-3 expression (fig. 353 
S7B) and IL-5 production (Fig. S7C) remained comparable after incubation over collagen-I or 354 
collagen-IV. However collagen-I selectively induced the most pronounced ILC2 shape change 355 
with characteristically elongated ILC2 cell bodies visible (Fig. 6, A and B). In amoeboid 356 
movement, force generation (protrusion and contraction) and force transduction (adhesion), 357 
are controlled by actomyosin cytoskeletal remodelling (56). We imaged f-actin localisation and 358 
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quantified ILC2 shape after 12h on the different ECM. ILC2 seeded on collagen-I were highly 359 
polarised with areas of f-actin accumulation (Fig. 6B) and had significantly greater cell area 360 
and perimeter (Fig. 6, C and D). Taken together these data indicate that collagen-I influences 361 
ILC2 shape towards the pro-migratory exploratory phenotype we described in vivo (Fig. 2 and 362 
3 F).  363 
 364 
Blocking collagen fibrillogenesis in vivo increases ILC2 dynamics and reduces 365 
eosinophil accumulation in the inflamed lung. 366 
We have previously demonstrated that epithelial cell derived TGF-β1, induced after rIL-33 367 
treatment, can drive ILC2 movement (34). Furthermore, our results show that collagen-I 368 
significantly alters ILC2 shape by elongating the cell body (Fig. 6). TGF-β has been shown to 369 
enhance collagen-I and III mRNA expression during remodeling and blocking collagen 370 
deposition restores baseline collagen levels (57). We observed changes to collagen geometry 371 
in the peribronchial space where ILC2 are highly dynamic after rIL-33 treatment (Fig. 5, D and 372 
E). Hence, we next investigated whether we could extend our findings from the 2D assays 373 
previously described in Fig 6 into in vivo 3D tissue by blocking newly synthesized collagen 374 
and measuring ILC2 movement after rIL-33 induced inflammation. The fibrillar structure of 375 
type 1 collagen morphology is stabilized by inter and intra molecular crosslinks initiated by 376 
lysyl oxidases whose expression can be inhibited by β-amino propionitrile (BAPN) (57). 377 
Following rIL-33 treatment, we administered BAPN i.p. Strikingly, mice that received rIL-33 378 
along with the collagen crosslinking inhibitor showed longer tracks depicted as individual 379 
tracks (Fig. 7A) and track overlay between treatments (Fig. 7B). Cell track quantification 380 
revealed that ILC2 from lungs of mice that were rIL-33 treated along with BAPN displayed 381 
increased ILC2 track speed (Fig. 7C), track length (Fig. 7D) and track displacement (Fig. 7E) 382 
compared to rIL-33 treated mice suggestive of a reduced interaction with the ECM.  383 
Although addition of BAPN altered ILC2 motility in rIL-33 treated mice, ILC numbers only 384 
slightly reduced in the lungs (Fig. 7F) with comparable ILC2 numbers in the BAL (Fig. 7G) and 385 
blood (Fig. 7H). We additionally tested if BAPN directly activated ILC2 by evaluating cytokine 386 
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production by ex vivo sorted ILC2 from rIL-33 treated IL-13 eGFP mice. Our results showed 387 
that within the time frame of 36 h post incubation, IL-5 production by ILC2 remained 388 
unchanged after incubation with collagen-I + BAPN or collagen-I alone (fig. S8A). Interestingly 389 
addition, of rCCL8 to the cultures significantly increased IL-5 production (fig. S8A). We next 390 
evaluated if blocking collagen fibrillogenesis in rIL-33 treated mice impacted on the 391 
inflammatory infiltrate in the lungs and altered lung function. rIL-33 + BAPN treated mice had 392 
unchanged lung function (Fig. 8A) and comparable numbers of airway macrophages (Fig. 8B), 393 
dendritic cells (Fig. 8C), neutrophils (Fig. 8D) compared to mice treated with rIL-33 alone. 394 
Interestingly, blocking collagen fibrillogenesis in rIL-33 treated mice significantly reduced the 395 
frequency of eosinophils (Fig. 8E) and lung CCL24 levels (Fig. 8F) while eosinophil motility 396 
remained unaltered compared to mice treated with rIL33 treated alone (movie S8, A and B) 397 
and further quantified by track length (fig. S8B) and track speed (fig. S8C). We finally 398 
compared eosinophil accumulation in the peribronchial region of the lungs where ILC2 399 
accumulate and found significantly lower number of eosinophils as demonstrated by congo 400 
red staining (Fig. 8G and H). 401 
Therefore, blocking newly synthesized collagen during rIL-33 treatment significantly changed 402 
ILC2 motility and the ensuing eosinophil accumulation. These data indicate that ILC2 403 
interactions with the ECM may impact their function and contribution to eosinophilic 404 
inflammation. 405 
 406 
Discussion: 407 
Immune cell recruitment in inflammation involves emigration of activated leukocytes from the 408 
vasculature across inflamed endothelium into the tissue space through activation of specific 409 
effector programs (58). The ensuing response must be robust enough to control infection or 410 
repair damage but sufficiently restrained so as to prevent excessive tissue damage and 411 
pathology. Mucosal surfaces, such as the lung, constantly encounter potentially harmful 412 
threats in the form of microbes, allergens and pollutants that can damage lung tissue and 413 
impair normal physiological lung function. Group 2 innate lymphoid cells (ILC2) are central in 414 
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orchestrating type-2 immunity (28) and promoting tissue repair (13). We have previously 415 
shown that during lung inflammation, in vivo and in vitro, TGF-β expression influences ILC2 416 
movement but the mechanisms which promote ILC2 migration are not well understood (34). 417 
Hence a more detailed spatio-temporal analysis of ILC2 induction and dynamics in the lung is 418 
of great importance to develop a thorough appreciation of ILC2 behaviour and function, and 419 
their interaction with other cells during type 2 inflammatory responses. Since ILC2 are a rare 420 
immune cell population in the lung at homeostasis (28), visualizing ILC2 by intravital imaging 421 
in the lungs of living animals has been challenging. Delivery of rIL-33 in mice drives type-2 422 
immunity and ILC2 expand robustly and produce large amounts of IL-13 (28, 34) even in the 423 
absence of T and B cells (42). In this report, by utilizing a model of rIL-33 or Alt driven lung 424 
inflammation in IL-13eGFP knock-in mice, combined with sophisticated lung imaging, we 425 
demonstrate for the first time that ILC2 are highly dynamic in the lung in vivo. Following an 426 
acute inflammatory exposure, ILC2 numbers in the lung increased substantially by around 30 427 
(Alt) - 100 (rIL-33) fold respectively. Simultaneously, our results show an incremental increase 428 
in the number of ILC2 in both the lung draining LN and circulation after Alt or rIL-33 induced 429 
inflammation. A recent study reported that administration of rIL-33 in mice promotes the egress 430 
of ILC2 progenitors (ILC2Ps) from the bone marrow to peripheral tissues while mice lacking 431 
IL-33 signalling had a significant accumulation of ILC2Ps in the bone marrow (59). This 432 
suggests that the rapid expansion in ILC2 numbers induced in the lung in our model of rIL-33 433 
inflammation could result as a consequence of recruitment of ILC2Ps from the BM rather than 434 
in situ proliferation of a small steady state resident precursor. In addition, there was no 435 
increase in ILC2 numbers in the spleen or non-lung draining lymph nodes indicating that 436 
intranasal rIL-33 signals for ILC precursors in the bone marrow to traffic to the lungs. Our 437 
imaging studies also depict ILC2 accumulation in the extra-vascular tissue surrounding large 438 
blood vessels again indicating that these cells are perhaps likely to be recent emigrants from 439 
the BM. 440 
 441 
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In the lung, we found that ILC2 mainly accumulate in the peribronchial / perivascular area and 442 
to a lesser extent in the parenchyma. The location of ILC2 in the peribronchial area is 443 
consistent with their postulated role in promoting epithelial repair. In a previous study, we 444 
showed that ILC2 in the airway lumen are primed to respond to epithelial cell derived TGF-β 445 
induced after rIL-33 administration, as a result of high cell surface expression of TGF-βRII, 446 
and that epithelial cell derived TGF-β enhanced the migratory activity of ILC2 (34). Hence a 447 
critical molecular communication exists between ILC2 and bronchial epithelial cells to promote 448 
ILC2 movement during lung inflammation and could explain why ILC2 home to the 449 
peribronchial region of the lung tissue.  450 
 451 
By using live lung slices, we demonstrated an amoeboid pattern of movement of lung ILC2 452 
after rIL-33 treatment. This observation was recapitulated in the lungs of live intact mice using 453 
lung intravital microscopy of rIL-33 treated IL13eGFP mice. We found that similar to our data 454 
in live lung slices, ILC2 were enriched in the lung tissue surrounding larger blood vessels 455 
rather than the alveolar capillaries and characteristically move in an amoeboid manner during 456 
locomotion. However, despite their functional and phenotypic similarities to CD4+ T cells, 457 
ILC2 differed markedly in their migratory behaviour moving faster and to greater distances 458 
than CD4+ T cells in the inflamed lung. The physical proximity of motile ILC2 to epithelial 459 
cells further supports the notion that ILC2 may directly influence epithelial cell function and 460 
vice versa and may not be restricted to communication via secreted cytokines but could 461 
result from physical receptor-ligand interactions. It is known that motility patterns and 462 
distances travelled by various leukocyte subpopulations differ (60). In our study, we find that 463 
lung ILC2 exhibit amoeboid pattern of movement travelling distances in the range of 100-464 
200µm perhaps displaying ’searching’ or ‘exploratory’ behaviour, consistent with their 465 
sentinel role at mucosal sites (61). Taken together, our data suggests that lung ILC2 may 466 
exhibit motility patterns similar to innate immune cells. This is consistent with findings in the 467 
skin, where dermal ILC2 patrol their environment with an average speed similar to that of 468 
dermal dendritic cells (38). This scanning behaviour of ILC2 may be suggestive of their need 469 
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to detect local alarmins or danger signals by damaged epithelial cells in the lung after an 470 
inflammatory insult. Furthermore, the migration of lung ILC2 in close association with bronchial 471 
epithelial cells seems likely to ensure that factors secreted by the epithelium, such as TGF-, 472 
can rapidly engage the ILC2. It presumably also ensures that signalling in the reverse 473 
direction, from the ILC2 to the epithelial cells, for promoting epithelial repair can take place 474 
efficiently.  475 
 476 
Factors driving leukocyte motility include the distribution of adhesion molecules on leukocytes, 477 
as well as chemotactic signals. It has been well established that lung ILC2 express both  1 478 
and 2 integrins at homeostasis and after Alt-induced inflammation (39). Furthermore, ILCs 479 
share many of the key features analogous to T cell populations, for example ILC2 and T cells 480 
both use the homing receptor CCR7 to actively migrate to lymphoid tissues (3). In addition, it 481 
has been shown recently that inflammatory iILC2, originating from precursors in the intestinal 482 
lamina propria express high levels of CCR9 and use sphingosine 1-phosphate receptors to 483 
exit the intestine into the lymph and move to distant sites like the lung where they display 484 
effector activity (15). Interestingly, progenitors to iILC2 do not exist in the lung and are not 485 
induced after inflammation induced via the intra nasal route (15). Hence, the chemokine 486 
migratory programs of ILC2 generated in the lung after intranasal instilled mediator driven 487 
inflammation have remained elusive until now and very little is understood about the process 488 
by which ILC2 are attracted to sites of immune insult in the lungs. At homeostasis, we found 489 
that CCR8 and CCR1 was expressed by the majority of murine lung ILC2, in contrast to other 490 
T cell subsets. However, following rIL-33 treatment, the percentage of CCR8 and CCR1 491 
expressing ILC2 further increased.   492 
 493 
In addition, TGF- acts as an ILC2 chemo-activator enhancing murine ILC2 migration in a 494 
non-directional manner. Furthermore, both PGD2 and to a much lesser extent IL-33 have been 495 
shown to be chemotactic for human skin- and blood-derived ILC2 (48). Interestingly, we show 496 
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for the first time that in addition to PGD2, CCL8 is chemotactic for ILC2 with nanomolar 497 
potency. We found that CCL8 deposits were strongly expressed in the peribronchial space 498 
where murine lung ILC2 accumulate. This could be attributed to the CCL8–CCR8 ligand-499 
receptor axis which has been shown to be crucial in localizing pathogenic Th2 cells to the site 500 
of eosinophilic inflammation and in driving the allergic process in the skin (62). To further 501 
explore this hypothesis, we blocked CCR8 receptor in rIL-33 treated mice and analysed effects 502 
on ILC2 motility. Our data strongly suggest that signalling via CCR8 is critical for ILC2 cytokine 503 
(IL-13 and IL-5) production as well as motility of IL-13+ activated ILC2. A variety of resident 504 
pulmonary cells secrete CCL8, the CCR8 ligand in mice. We find that lung airway 505 
macrophages are the pre-dominant cellular source of CCL8 in rIL-33 treated mice. Our data 506 
suggest a previously undescribed model where macrophage derived CCL8 acts to increase 507 
ILC2 accumulation to areas proximal to epithelial cells. 508 
 509 
Overall, our results provide insights into the independent and distinct migration pathways ILC2 510 
utilize in contrast to T cells. Extracellular matrix proteins such as collagens are well-known to 511 
interact with leukocytes by directly binding to cell surface receptors (63). In this respect, 512 
changes to subepithelial collagen and extracellular matrix protein deposition are important 513 
pathophysiological components of airway remodeling in Th2 driven lung inflammation. We find 514 
strong fibrillar collagen deposition around bronchioles and associated vessels in both rIL33-515 
treated and control PCLS where lung ILC2 accumulate. Interestingly rIL-33 treated mice 516 
showed quantitative differences in both correlation and homogeneity parameters of fibrillar 517 
collagen geometry compared to control mice. rIL-33 induced epithelial TGF- is chemoactive 518 
for ILC2 and administration of TGF- in mice increases collagen-I mRNA expression in mouse 519 
lungs (49, 57). This suggests that altered collagen distribution as a result of rIL-33 induced 520 
inflammation may influence ILC2 migratory programs. In line with this, our in vitro 2D migration 521 
assays indicate that collagen-I exclusively alters ILC2 morphology with enhanced cell spread 522 
and elongation of cell body. Hence in vivo, collagen-I fibres may support a more polarized 523 
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ILC2 morphology, by increasing ILC2 traction, reducing ILC2 speed and allowing for longer 524 
dwell times in specific sites of inflammation in the lung. Cross-links are essential for the 525 
mechanical stability of collagen and have been shown to control T cell mobility (64). To test 526 
the overall contribution of newly synthesized collagen on ILC2 dynamics, we used beta-527 
aminopropionitrile (BAPN) to block the formation of new collagen cross-links by inhibiting the 528 
enzyme lysyloxidase. Interestingly, blockade of collagen fibrillogenesis significantly increased 529 
ILC2 speed and travel distance after rIL-33 treatment. Hence suggesting that reduced collagen 530 
stability, resulting as a consequence of blocking new collagen fibrillogenesis may disrupt a 531 
controlled receptor-ligand interaction of ILC2 with collagen-I fibres, increasing overall 532 
dynamics of ILC2. Intriguingly, although collagen-I blocking increased ILC2 movement, rIL-33 533 
induced eosinophilia was significantly reduced in the lungs of these mice. We have previously 534 
reported that after house dust mite treatment in mice, chemoactive epithelial derived TGF- is 535 
essential for ILC2 activation and critically controls all hallmarks features of allergic responses 536 
including airway hyperresponsiveness and eosinophilia (34). Inferring from this knowledge our 537 
data suggests that although the initial cytokine driven instruction from structural cells initiates 538 
ILC2 movement, components of the inflamed lung environment namely, CCL8-CCR8 539 
signaling and collagen-I are critical for regulating controlled ILC2 accumulation and dynamics 540 
imperative for ensuring robust type-2 inflammation. Hence although TGF-β serves as a 541 
chemokinetic mediator, CCL8 induced after rIL-33 treatment is an important chemotactic 542 
signal that mediates ILC2 motility and cytokine production via CCR8 receptor. Furthermore, 543 
the difference in interfibrillar geometry of collagen fibrils alters ILC2 migratory patterns and the 544 
dwell time of ILC2 with collagen-fibrils is a critical factor towards ILC2 behaviour and function 545 
in type-2 inflammation. Thus combined environmental signals from damaged lung tissue act 546 
in concert to mechanistically drive ILC2 migratory patterns in the inflamed lung. 547 
 548 
ILC2 are defined by the combination of several extracellular and intracellular markers. Here 549 
we use multicolour flow cytometry of cell suspensions from dissociated lung tissue to identify 550 
and quantify these cells, but this approach loses spatiotemporal information by 551 
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definition.  Therefore, we used a combination of imaging using IL13-GFP reporter mice in 552 
combination with a handful of markers and dyes and detailed multicolour flow cytometry 553 
together to mitigate potential misidentification of the cells.  However, in an ideal experiment 554 
we would be able to image tens of markers simultaneously.  Newer approaches (for eg: 555 
imaging mass cytometry) are starting to address this, but none allow live organism / cell / 556 
tissue imaging to directly address the spatiotemporal dynamics of these populations, a 557 
significant challenge in the field.    558 
 559 
Overall, using highly sophisticated imaging techniques, we reveal how ILC2 migrate within 560 
an inflamed tissue, interact with adjacent cells and lung environmental factors during a type-561 
2 inflammatory response. Specifically, we show that lung ILC2 are highly motile in vivo and 562 
exhibit an exploratory amoeboid pattern of movement during inflammation. Additionally, we 563 
identify signature chemokine receptors employed by ILC2 to home to inflammatory sites in the 564 
lung. Our data provide novel insights into the mechanism by which diverse lung environmental 565 
factors combine to control ILC2 migration and provide direct evidence for collagen-I in 566 
exclusively regulating ILC2 shape and polarity, thereby influencing the outcome of an 567 
inflammatory response. Imaging these dynamic cellular events in real-time in the lungs of 568 
living animals has provided an important visual platform that could be employed for further 569 
interrogation of ILC2 and other immune cell functions in the context of allergen or pathogen 570 
driven Th2 inflammation.   571 
 572 
 573 
Materials and Methods 574 
 575 
Mice 576 
Adult female IL13-eGFP (kind gift from A.N. McKenzie, MRC Laboratory of Molecular Biology, 577 
Cambridge) (28) were used for experiments between 7 and 10 weeks of age. Mice were 578 
housed in specific-pathogen-free conditions and given food and water ad libitum. All 579 
procedures were conducted in accordance to the institutional guidelines and under the 580 
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approval of our Home Office project licence (granted under the Animals (Scientific Procedures) 581 
Act 1986). Mice were administered 10μg (Alternaria alternata) extract (Greer Laboratories) in 582 
25μl of PBS intranasally 3 times a week for 1 week or PBS alone as controls. Alternatively, 583 
carrier-free recombinant murine rIL-33 (1μg per dose in 25μl PBS) (eBioscience) or PBS was 584 
administered 3 times a week for 1 week. Mice were culled 24hrs after the final cytokine or 585 
allergen dose.  586 
 587 
Live Precision Cut Lung Slices 588 
Ex vivo cultured precision-cut lung slices (PCLS) provided a 3D cell culture model to image 589 
ILC2 dynamics within the lung microenvironment and was adapted and modified from a 590 
previously described protocol (65). Briefly, prior to slicing, lungs were inflated with 0.8ml 591 
volume of 2% low melting agarose (Thermofisher) prepared in PBS. Following inflation lungs 592 
were carefully dissected out and placed in HBSS containing 2.5% HEPES (GIBCO, Life 593 
Technologies). The intact left superior lung lobe was excised and 200µm transverse sections 594 
were prepared from the upper 1mm region of the left superior lung lobe using a Compresstome 595 
VF-300 vibrating microtome (Precisionary Instruments). PCLS were incubated in complete 596 
RPMI (10% FCS, 2 mM L-glutamine, 100U/ml penicillin/streptomycin) (GIBCO, Life 597 
Technologies) for 15mins at 37°C to wash off excess agarose surrounding the tissue. 598 
Antibodies were prepared in complete DMEM solution and lung explants were incubated in 599 
staining solution for 1.5hrs at 37°C prior to imaging. Time lapse videos depicting ILC2 600 
movement were generated over an hour using an inverted laser-scanning confocal 601 
microscope (SP5, Leica microsystems). Videos were quantified using Imaris version 8.1 602 
(BitPlane, Oxford Instruments) and ILC2 track speed, length and displacement were quantified 603 
using Motilitylab software. 604 
 605 
Table S1. Antibodies used for imaging of PCLS 606 
Antibody Clone Fluorochrome Target species Manufacturer 
EPCAM G8.8 PE Mouse Biolegend 
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CD4 RM4-5 BV421 Mouse Biolegend 
CD31 390 Alexa-647 Mouse Biolegend 
 607 
Intravital microscopy  608 
Mouse lung intravital microscopy was performed as previously described (44, 66). Briefly, 609 
anaesthetised and mechanically ventilated mice were placed on a heat-mat in a right lateral 610 
position. A small custom-built circular suction chamber was surgically inserted using a small 611 
incision between the ribs of the mice for imaging on an upright laser-scanning confocal 612 
microscope with Hybrid detectors (Leica SP5). Gentle suction was applied via the vacuum 613 
port to bring the cover slip contained in the chamber into contact with the lung and stabilise 614 
the tissue. Time-lapse videos depicting ILC2 movement were generated using 488, 54 and 615 
633nm laser lines through a 25x 0.95 N.A. long working distance water immersion objective.  616 
 617 
Fixed Cell / PCLS imaging 618 
Phalloidin stained ILC and fixed PCLS from IL-33 reported mice were imaged using a Zeiss 619 
LSM 880 Airyscan NLO system. DAPI was excited using a 405nm diode laser, Phalloidin 620 
AlexaFlour488 was excited at 488nm using an argon-ion laser and detected using a sub-Airy 621 
detector 32-element array (Airyscan) and processed using ‘auto’ 3D Airyscan processing 622 
options. Airyscan z-stacks were acquired and Imaris (Bitplane) was used to visualise each 623 
cell. SHG signals (produced at a central wavelength of 475nm) were collected from fixed PCLS 624 
using a Coherent Chameleon Discovery femtosecond pulsed laser tuned to 950 nm and 625 
collected using a non-descanned GaAsP detector with 450±50nm detection filter. A 25x 1.0 626 
N.A. zeiss long working distance water immersion objective was used to collect all images.   627 
 628 
 629 
SHG Analysis 630 
50μm z-stacks were imaged over a region of 425.1μm by 425.1, with at least three stacks 631 
/mouse (n = 6 mice / condition). GLCM was performed similarly to previous studies (67, 68) 632 
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Briefly, Image J (NIH) and the Norwegian University of Life Sciences (UMB) GLCM plugin was 633 
used for the texture analysis, modified to run automatically through the four directions, for each 634 
of the 100 comparison distances. A maximum projection image was automatically thresholded 635 
to produce a mask that was then applied to remove background noise bias in the GLCM 636 
analysis by selecting only the collagen SHG signal. The masked image was then passed to 637 
the modified GLCM texture plugin. The data files produced were processed using an ImageJ 638 
macro to output both the mean and individual values for each texture parameter for each 639 
image. These were then imported into Prism (GraphPad), where exponential decay models 640 
were fitted to the data. 641 
 642 
Cell isolation (BAL, Lung and lung dLN) 643 
The airways were washed three times with 400μl of PBS and bronchoalveolar lavage fluid was 644 
collected. Following centrifugation of the BAL fluid supernatants were stored at -80°C for 645 
further analysis and cells were resuspended in 500μl of complete RPMI media (10% FCS, 646 
2mM L-glutamine, 100U/ml penicillin/streptomycin) (GIBCO, Life Technologies). For lung cell 647 
isolation, the left lung lobes were cut into small pieces and digested in complete media 648 
supplemented with 0.15mg/ml collagenase (Type D; Roche Diagnostics) and 25μg/ml DNase 649 
(Type 1; Roche Diagnostics) for 1h at 37°C. Lung homogenate obtained was then filtered 650 
through a 70μm sieve (BD Bioscience), washed, and resuspended in 1ml of complete media. 651 
Erylysis was performed on 200μl whole blood and leukocytes were washed twice and then 652 
then resuspended in 1ml of complete media. 653 
 654 
Flow Cytometry and intracellular staining 655 
For phenotyping ILC2 in IL-13 eGFP mice by flow cytometry, ILC2 were defined as live, singlet, 656 
lymphoid, GFP+CD45+ lineageneg (Lineage cocktail: TCRβ, TCRγδ, CD3e, CD5, CD19, 657 
CD11b, CD11c, FCεR1, GR-1, F4/80, NKp46 and TER-119) CD3- NKp46-, 658 
CD90.2+/CD127+/KLRG1+/CD25var cells with positive intracellular IL-13 and IL-5 staining.  659 
 660 
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For intracellular cytokine staining, cells were stimulated with PMA (Sigma-Aldrich) and 661 
ionomycin (EMD Chemicals) in the presence of Brefeldin A (Sigma-Aldrich) and incubated for 662 
4h at 37°C. Following stimulation, cells were washed and incubated for 20min with anti-663 
CD16/32 (BD Pharmingen) prior to staining for extracellular antigens in 5% FCS/1% BSA in 664 
PBS for 30min at 4°C. All antibodies were purchased from eBioscience (table 2) with the 665 
exception of CD31, EpCAM, CD4 (Biolegend) also shown in table 1. Following staining for 666 
extracellular markers, cells were fixed with IC fixation buffer (E-Bioscience) for 10 mins at 667 
room temperature. Cells were then washed and stained for intracellular antigens using the 668 
Intracellular Fixation & Permeabilization Buffer Set (E Bioscience) or Foxp3 / Transcription 669 
Factor Staining Buffer Set (E-Bioscience) for GATA-3 staining.  670 
Analysis was performed with LSRFortessa III and cell sorting on FACSAria III (BD 671 
Biosciences). 672 
 673 
Table S2. Antibodies used for flow cytometry 674 
. 675 
Antibody Clone Fluorochrome Target 
species 
Manufacturer  
TCR-β H57-597 APC Mouse E Bioscience  
TCR-γδ ebio GL3 APC Mouse E Bioscience  
TER-119 TER-119 APC Mouse E Bioscience  
CD19 ebio ID3 APC Mouse E Bioscience  
CD11b M1/70 APC Mouse E Bioscience  
CD5 53-7.3 APC Mouse E Bioscience  
F4/80 BM8 APC Mouse E Bioscience  
FCεR1 MAR1 APC Mouse E Bioscience  
GR-1 RB6-8C5 APC Mouse E Bioscience  
CD11c N418 APC Mouse E Bioscience  
NKp46 29A1.4 PE-Dazzle Mouse E Bioscience  
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CD45 30-F11 PerCP Cy5.5 Mouse E Bioscience  
CD3e 145-2C11 APC-Cy7 Mouse E Bioscience  
KLRG-1 2F1/KLRG1 PE-Cy7 Mouse E Bioscience  
CD90.2 53-2.1 BV605 Mouse E Bioscience  
CD25 PC61 BV510 Mouse E Bioscience  
CD127 A7R34 BV711 Mouse E Bioscience  
IL-13 ebio 13A PE Mouse E Bioscience  
IL-5 TRFK5 BV421 Mouse E Bioscience  
GATA-3 TWAJ PerCP-eFluor 
710 
Mouse E Bioscience  
 676 
 677 
Lung histology and staining  678 
 679 
Paraffin embedded lung sections (4-micron thickness) were stained with haematoxylin and 680 
Congo red-dyes. Images were taken under polarised light using an upright dry 40x objective. 681 
The number of eosinophils in the peribronchial space were quantified and corrected for the 682 
surface area scored.  683 
 684 
Human ILC2 bulk cultures 685 
ILC2 were enriched from whole blood using RosetteSepTM Human ILC2 Enrichment Kit 686 
(STEMCELL Technologies) and further sorted by FACs using CD45+ Lineageneg (CD1a, CD3, 687 
CD4, CD5, CD8, CD11c, CD14, CD16, CD19, CD20, CD34, FcγRI and CD123) (Biolegend), 688 
CD161+, CD127+, CRTH2+ and C-Kitvar (Biolegend). ILC2 were bulk cultured in IL-2, IL-7 689 
(5ng/ml) and IL-33 (10ng/ml) (eBioscience) and cytokines and medium were replenished 690 
every 3-4 days. For investigations involving humans ILC2 isolation, an informed consent was 691 
obtained and the nature and possible consequences of the studies were explained to all 692 
donors. 693 
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 694 
Table S3. Antibodies used for sorting human ILC2 695 
 696 
Antibody Clone Fluorochrome Target species Manufacturer 
CD11c 3.9 FITC Human Biolegend 
CD123 6H6 FITC Human Biolegend 
CD14 63D3 FITC Human Biolegend 
CD16 B73.1 FITC Human Biolegend 
CD161 HP-3G10 PECy7 Human Biolegend 
CD19 HIB19 FITC Human Biolegend 
CD1a HI149 FITC Human Biolegend 
CD20 2H7 FITC Human Biolegend 
CD3 OKT3 FITC Human Biolegend 
CD34 581 FITC Human Biolegend 
CD4 OKT4 FITC Human Biolegend 
CD5 L17F12 FITC Human Biolegend 
CD127 A019D5 PerCP5.5 Human Biolegend 
CRTH2 BM16 BV421 Human Biolegend 
CD45 H130 BV605 Human Biolegend 
 697 
CCR8 antibody blocking and rCCL8 treatment 698 
CCR8 neutralisation studies were performed similar to previous reports (69). IL-13eGFP and 699 
balb/c mice were i.p. injected with 5µg purified anti-mouse CD198 (CCR8) antibody, (Clone: 700 
SA214G2) or purified Rat IgG2b, κ Isotype Ctrl Antibody two days prior to first dose of rIL-33 701 
treatment and then combined with each of the three rIL-33 doses. Mice were analysed 24h 702 
post the third dose.  Alternately 10µg Recombinant Mouse CCL8 (MCP-2) (Biolegend) was 703 
administered i.n. at the time of the three rIL-33 doses.   704 
 705 
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β-aminoproprionitrile (BAPN) treatment 706 
BAPN treatment was carried out similar to previous reports (70). IL-13 eGFP or balb/c mice 707 
were i.p. injected with β-aminoproprionitrile (BAPN) (100 mg/kg, Sigma) dissolved in PBS and 708 
administered in 200 μl volume on day -1 and then daily for a week over the course of rIL-33 709 
treatment.  710 
 711 
Measurement of Airway hyperesponsiveness 712 
Airway resistance in mice was evaluated adopting the flexiVent  small  animal ventilator 713 
(SciReq) as previously described (29) Prior to procedure mice were anesthetized with a 714 
combination of pentobarbital sodium (50 mg/kg, administered intraperitoneally) and ketamine 715 
(100 mg/kg, administered intramuscularly), tracheostomized, and connected to the flexiVent 716 
ventilator using a blunt-ended 19-gauge needle. The mice were ventilated by maintaining an 717 
average breathing frequency of 150 breaths/min, tidal volume of 10 ml/kg body weight and 718 
positive end-expiratory pressure of about 2 cm H2O. Differences in resistance to increasing 719 
concentrations of nebulized methacholine (3- 100 mg/ml) were analysed from the snap-shot 720 
perturbation measurements. The data was then plotted using multiple linear regression to the 721 
single-compartment model in the following form: pressure = resistance × flow + elastance × 722 
volume + fitting constant. 723 
 724 
Chemotaxis Assay 725 
Assays of chemotactic responsiveness were carried out as previously described using 96-well 726 
ChemoTx® plates with 5μm pores (Neuroprobe). Migrating cells were detected by the use of 727 
CellTiterGlo® Dye (Promega) and resulting luminescence measured using a TopCount 728 
scintillation counter (PerkinElmer). In all experiments, each data point was assayed in 729 
duplicate. Data are reported as Chemotactic Indices, defined as the migratory response to a 730 
particular stimulus divided by the migratory response to media alone.  731 
 732 
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Analysis of ILC2 dynamics on ECM proteins 733 
Human ILC2 were obtained by sorting and differentiating ILC2 from peripheral blood. ILC2 734 
lines were seeded on tissue culture plates coated with 10% FBS, 50µg/ml of fibronectin, 735 
collagen-I, and -IV. Human ILC2 dynamics was imaged on the JuLI imaging system for a 736 
period of 12h. ILC2 dynamics quantified as changes in speed and displacement were 737 
quantified using Image J software.  738 
 739 
Statistical analysis 740 
All data were analyzed using Graph Pad Prism 7. Time series videos were analysed and cell 741 
tracks were quantified by Imaris software. Tracks were imported to Prism for quantifying track 742 
length and track speed. Additionally tracks were imported into MotilityLab software to display 743 
tracks from centroid and differences in mean square displacement.  All line graphs and bar 744 
charts are expressed as mean ±SD and data analyzed with non-parametric Mann-Whitney U 745 
test where significance was defined as ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and,∗∗∗∗ p < 0.0001. 746 
 747 
Supplementary Materials 748 
 749 
Figure S1 Gating strategy for identification of ILC2 populations, related to Fig. 1 A-C. 750 
Figure S2. Quantification of ILC2 in different tissues, related to Fig. 1 A-C. 751 
Figure S3. Gating strategy for identification of ILC2 populations based on GATA-3 expression, 752 
related to Fig. 1 A-C. 753 
Figure S4. Distribution of ILC2 and CD4+ T cells in rIL33 treated mice lungs, related to Fig. 1 754 
D and F. 755 
Figure S5. Chemokine receptor expression on ILC, related to Fig 4. (A-B). 756 
Figure S6. Phenotype and IL-13 production by human ILC2 lines, related to figures 4 and 5. 757 
Figure S7. ILC2 motility on extracellular matrix proteins, collagen-III and proteoglycans 758 
Versican and tenascin-C, related to figure 5A-C. 759 
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Figure S8. BAPN fails to affect ILC2 cytokine production and eosinophil movement, related to 760 
figure 8G. 761 
Movie S1. Time-lapse imaging of rIL-33 treated mouse lung PCLS showing ILC2 movement 762 
and location, related to Fig. 2 A. 763 
Movie S2. Time-lapse imaging of rIL-33 treated mouse lung PCLS depicting differences in 764 
movement of independent ILC2, related to Fig. 2 B. 765 
Movie S3. Time-lapse imaging of rIL-33 treated mouse lung PCLS depicting high power videos 766 
differences in movement of independent ILC2, related to Fig. 2 C. 767 
Movie S4. Intra-vital imaging of rIL-33 treated mouse lung depicting amoeboid ILC2 768 
movement, related to Fig. 2 H. 769 
Movie S5. Influence of ILC2 survival and cytokines on ILC2 motility, related to figure 5A-C. 770 
Movie S6. Time-lapse imaging of lung PCLS from rIL-33 treated mouse treated with anti-CCR8 771 
Ab or Isotype Ab, related to Fig. 4I. 772 
Movie S7. Collagen-I induced ILC2 shape change and elongation of cell body, related to Fig. 773 
5 A. 774 
Movie S8. Time-lapse imaging of a lung PCLS assessing the effect of BAPN on rIL-33 treated 775 
mouse lung eosinophil movement, related to Fig. 8G. 776 
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Main text figure legends: 1008 
Fig 1. The number of ILC2 rapidly increase in the peribronchial / perivascular region 1009 
after rIL-33 treatment. IL13-eGFP mice were treated with 3 doses of rIL-33 (1µg per dose), 1010 
Alt (10µg) or PBS (25µl) over 1 week and culled 24h after the final dose. The frequency of 1011 
ILC2 (GFP
+
CD45
+
Lin
neg
CD3
-
NKp46
-
CD127
+
CD90.2
+
KLRG1
+
CD25
var
IL-13
+
IL-5
+
) in the (A) 1012 
airways (BAL fluid), (B) lung and (C) lung draining lymph nodes (mediastinal). Live viable 1013 
precision cut lung slices of 200µm thickness were obtained and stained for CD31 (Magenta, 1014 
the lung structure and blood vessels), CD4 (cyan, T cells, orange arrow), EpCAM (Red, to 1015 
37 
 
visualise bronchial epithelium) and GFP (ILC2, white arrow). Images of 1024µm x 1024µm 1016 
field of view (FOV) were taken under a 20x objective using an inverted confocal microscope. 1017 
(D) Images showing ILC2 (GFP
+
CD4
-
) CD4+ T cells (CD4+GFP-) location in PBS, rIL-33 and 1018 
Alt treated mice, scale bar, 150 μm. (E) Number of ILC2 (GFP
+
CD4
-
) in lung sections per FOV 1019 
taken under a 10x objective. (F) Schematic illustration of the lung depicting the anatomical 1020 
location in the lung where precision cut lung slices were prepared. Representative images 1021 
show two regions of the lung slice from a rIL-33 treated mouse showing distribution of ILC2 1022 
and CD4+ T cells, scale bar 150 μm. n = 4 mice per group (Mock(PBS)), n= 6 mice per group 1023 
(Alt or rIL-33 treatment). Data representative of 4 experiments.  
∗
p < 0.05, 
∗∗
p < 0.01, 
∗∗∗
p < 1024 
0.001 and, 
∗∗∗∗
 p < 0.0001. 1025 
 1026 
Fig 2. rIL-33 stimulation induces ILC2 motility around blood vessels and airways. IL13-1027 
eGFP mice were treated with 3 doses of rIL-33 (1µg per dose), over 1 week and culled 24h 1028 
after the final dose. Live viable precision cut lung slices (PCLS) of 200µm thickness were 1029 
obtained and stained for CD31 (Magenta, the lung structure and blood vessels), CD4 (cyan, 1030 
T cells, orange arrow), EpCAM (Red, to visualise bronchial epithelium) and GFP (ILC2, white 1031 
arrow), and time-lapse video taken (1024µm x 1024µm field of view (FOV), 45 min duration 1032 
under a 20x objective using an inverted confocal microscope) (A) Static image depicting the 1033 
location of ILC2 and CD4
+
 T cells, scale bar 100 μm. (B) Zoomed in section of the blood vessel 1034 
in figure 2A, scale bar 20 μm. (C) High power images of boxed cells in figure 2B showing 1035 
differences in pattern of cell movement (oscillatory vs amoeboid movement). ILC2 and CD4
+
 1036 
T cells dynamics were tracked and plotted as (D) individual tracks or (E) tracks commencing 1037 
from centroid and overlaid. (F) Track speed, (G) track length and (H) track displacement were 1038 
quantified. Representative images shown in (A-C) are from rIL-33 treated mice, where n = 6 1039 
mice per treatment (3 slices per mouse were imaged). For (F-H) in box and whiskers plots, 1040 
38 
 
each dot represents an individual cell. Data are representative from 4 experiments where n = 1041 
6 mice per treatment. 
∗
p < 0.05, 
∗∗
p < 0.01, 
∗∗∗
p < 0.001 and, 
∗∗∗∗
 p < 0.0001.  1042 
 1043 
Fig 3. rIL-33 stimulation induces ILC2 motility around blood vessels and airways. IL13-1044 
eGFP mice were treated with 3 doses of rIL-33 (1µg per dose) or Alt (10µg) over 1 week. Live 1045 
precision cut lung slices were obtained and ILC2 dynamics were compared between the two 1046 
and the differences were plotted as (A) individual tracks and (B) tracks commencing from 1047 
centroid and overlaid. Differences in tracks between treatments were quantified as (C) track 1048 
speed, (D) track length  and (E) track displacement. Intravital microscopy (IVM) was performed 1049 
in live IL-13eGFP mice after rIL-33 treatment (one 512µm x 512µm field of view (FOV) in a 1-1050 
hour-duration video). (F) Static images of different frames captured during the course of the 1051 
video depicting amoeboid shape changes of ILC2 at separate time-points, scale bar 20 μm. n 1052 
≥ 4 mice per group. Data representative of 4 experiments. 
∗
p < 0.05, 
∗∗
p < 0.01, 
∗∗∗
p < 0.001 1053 
and, ∗∗∗∗ p < 0.0001. Quantifications from (A-E) are representative of 4 experiments, where 1054 
n = 6 mice per treatment (3 slices per mouse were imaged). For (F) IVM images are 1055 
representative of 6 individual IL-33 treated mice. 
∗
p < 0.05, 
∗∗
p < 0.01, 
∗∗∗
p < 0.001, and, 
∗∗∗∗
 p 1056 
< 0.0001.   1057 
 1058 
Fig 4. ILC2 utilize distinct chemotactic pathways to home to inflammatory sites in the 1059 
lung. IL13-eGFP mice were treated with 3 doses of rIL-33 (1µg per dose) or PBS (25µl), over 1060 
1 week and culled 24h after the final dose. (A) The percentage of murine ILC2 1061 
(CD45
+
Lin
neg
NKp46
-
CD3
-
) expressing CCR1, CCR4 and CCR8. CCL8 levels in murine (B) 1062 
BAL and (C) lung. (D) Location of CCL8 expression and ILC2 and (E) quantified CCL8 1063 
deposits in PCLS stained for CD31 (Magenta, the lung structure and blood vessels), CCL8 1064 
(cyan, yellow arrow), EpCAM (Red, to visualise bronchial epithelium) and GFP (ILC2, white 1065 
arrow), images of 1024µm x 1024µm FOV, scale bar 150 μm. Human ILC2 lines were 1066 
generated and migration to varying concentrations of (F) PGD
2
 and (G) CCL8 were 1067 
39 
 
determined. (H) Peak migratory responses of a human ILC2 cell line to IL-25, TGF-β, rIL-33, 1068 
CCL8 and PGD
2
. IL13-eGFP mice treated with rIL-33 were also treated with 5µg purified anti-1069 
mouse CCR8 antibody i.p., rCCL8 i.n. or an isotype control and PCLS obtained and stained.  1070 
(I) Localisation of ILC2 in live PCLS. (J) Number of ILC2 per FOV under 10x objective. Time-1071 
lapse imaging of 45 min duration was performed and ILC2 (K) track from centroid, (L) track 1072 
length and (M) track speed and (N) track displacement were quantified. In box and whiskers 1073 
graphs each data point represents an individual cell. Balb/c mice treated with rIL-33 were 1074 
further treated with rCCL8, αCCR8 or Isotype control antibody. (O) Percentage of IL-13
+
IL-5
+
 1075 
ILC2 (CD45
+
lin
-
NKp46
-
CD3
-
GATA-3
+
). (P) Representation Histogram of MFI of IL-13 and IL-5 1076 
and quantification of MFI for (Q) IL-13 and (R) IL-5 from GATA+ ILC2.
 
For panels A-E n ≥ 4 1077 
mice per group. Data representative of 4 experiments.  For panels F-H n = 3 individual donors. 1078 
Data representative of 3 experiments. For panels I-R, n = 5 mice per group. Data 1079 
representative of 2 experiments ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and,∗∗∗∗ p < 0.0001. 1080 
 1081 
  1082 
Fig 5. Extracellular matrix proteins, collagen-IV and fibronectin, promote increased 1083 
ILC2 motility. Human ILC2 lines were seeded on tissue culture plates coated with either 10% 1084 
FBS, fibronectin, collagen-I, collagen-IV or serum free coating (control) for 24h. Cell movement 1085 
was imaged via the JuLI imaging system and plotted as (A) individual tracks, (B) track speed 1086 
dot plots and (C) track speed spider plot. IL13-eGFP mice were treated with 3 doses of rIL-33 1087 
(1µg per dose) or PBS (25µl), over 1 week and culled 24h after the final dose PCLS obtained. 1088 
(D) SHG imaging of PCLS revealing collagen fibres, representative maximum intensity 1089 
projections, scale bar 50µm. (E) GLCM analysis of SHG imaging. (F) Images of Fibronectin 1090 
expression and localisation. PCLS stained for CD31 (Magenta, the lung structure and blood 1091 
vessels), Fibronectin (cyan, yellow arrow), EpCAM (Red, to visualise bronchial epithelium) 1092 
and GFP (ILC2, white arrow) and images of 1024µm x 1024µm field of view (FOV) were taken, 1093 
scale bar 150µm. For panels A-C, n = 3 donors (in triplicate). Data representative of 3 1094 
40 
 
experiments. For panels D-F n = 6 (in triplicate). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and,∗∗∗∗, 1095 
**** P < 0.0001. 1096 
 1097 
  1098 
Fig 6. Collagen-I enhances ILC2 actin cytoskeletal remodelling and polarity. Human ILC2 1099 
lines were seeded on tissue culture plates coated with either 10% FBS, fibronectin, collagen-1100 
I, collagen-IV or serum free coating (control) and imaged after 12 hours. (A) Bright field images 1101 
depicting change in shape. (B) Actin remodelling following staining with Phalloidin (green) and 1102 
DAPI (cyan) and imaging using Airyscan detection (maximum intensity projections), scale bar 1103 
5µm. (C) Cell area. (D) Cell perimeter. n = 3 donors. Data representative of 2 experiments. *** 1104 
P < 0.001. 1105 
 1106 
Fig 7. Blocking collagen fibrillogenesis in vivo increases ILC2 dynamics in the inflamed 1107 
lung. IL13-eGFP mice treated with rIL-33 were further treated with (BAPN) along with controls 1108 
were culled 24 hours after the final dose. ILC2 dynamics from live PCLS were plotted as either 1109 
(A) individual tracks or (B) tracks commencing from centroid and overlaid. Differences in 1110 
tracks between treatments were quantified as (C) track speed, (D) track length and (E) track 1111 
displacement. Total ILC2 () in (F) Lungs, (G) BAL and (H) Blood were enumerated. For panels 1112 
A-E n ≥ 4 mice per group. Data representative of 4 experiments. For panels F-H n = 6 mice 1113 
per group. Data representative of 2 experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P 1114 
< 0.0001. 1115 
 1116 
Fig 8. Blocking collagen fibrillogenesis reduces eosinophil accumulation in the 1117 
inflamed lung. Balb/c mice were treated with rIL-33 or PBS with or without BAPN.  (A) Airway 1118 
responsiveness to methacholine. Lung (B) alveolar macrophages (AM), (C) dendtitic cells 1119 
(DC), (D) neutrophils and (E) were enumerated by flow cytometry. (F) CCL24 protein in lung 1120 
tissue. (G) Congo red stained eosinophils (blue arrow) in lung histological samples. scale bar 1121 
50µm H Quantification of eosinophil from histological samples. For panels A-E n ≥ 6 mice per 1122 
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group. Data representative of 2 experiments. For panels G and H n ≥ 4 mice per group. Data 1123 
representative of 2 experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. 1124 
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Fig. S1. Gating strategy for identification of ILC2 populations, related to Fig. 1 A-C. IL13-eGFP mice treated 
with 3 doses or rIL-33 (1µg per dose) over 1 week and culled 24h after the final dose. Cells were pre-gated on 
lymphoid, live (determined using a fixable live dead dye), lineage and frequencies of GFP+CD45+ cells among 
lineage positive versus lineage negative cells was evaluated in (A). (B) ILC2 were defined by pre-gating on 
lymphoid, live (determined using a fixable live dead dye), GFP+CD3-NKp46- cells that were lineage (TCRβ, TCRγδ, 
CD5, CD19, CD11b, CD11c, FCεR1, GR-1, F4/80, and TER-119) negative cells and co-expressed intracellular IL-
13 and surface expression of CD90.2, KLRG-1, CD127 as shown in histogram plots.   
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Fig. S2. Quantification of ILC2 in different tissues, related to Fig. 1 A-C. Il13-eGFP mice treated with 
3 doses of rIL-33 (1µg per dose) or PBS (25µl) over 1 week and culled 24h after the final dose. ILC2 number 
in lungs, blood, bone marrow (BM), Spleen, Inguinal lymph node (LN), lung draining LN and mesenteric 
LN. n ≥ 6 mice per group. Data representative of 2 experiments. 
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Fig. S3. Gating strategy for identification of ILC2 populations based on GATA-3 expression, 
related to Fig. 1 A-C. ILC2 were identified by gating on CD45+ cells that were lineage neg (lin-) (Lineage 
cocktail: TCRβ, TCRγδ, CD5, CD19, CD11b, CD11c, FCεR1, GR-1, F4/80, and TER-119) lymphocytes 
that were additionally CD3e- and NKp46- and expressed GATA-3 as shown in (A). (B) shows % of GATA-
3+ ILC2 in lungs of mock, Alt and IL-33 treated mice which were further quantified in number as shown in 
(C) and co-expressed IL-13 and IL-5 (D). ILC2 were further evaluated for percent expression of CD90.2 
(E), KLRG-1(F), CD127 (G) and CD25 (H). Data shown for are from one of 4 independent experiments 
with a total of n ≥ 6 mice per group, * P < 0.05, ** P < 0.01, *** P < 0.001 and ****P < 0.0001   . 
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  Fig. S4. Distribution of ILC2 and CD4+ T cells in rIL33 treated mice lungs, related to Fig. 1 D and 
F. IL13-eGFP mice were treated with 3 doses of rIL-33 (1µg per dose), over 1 week and culled 24h after 
the final dose. (A) Live viable precision cut lung slices (PCLS) of 200µm thickness were obtained and 
stained for CD31 (Magenta, the lung structure and blood vessels), CD4 (cyan, T cells, orange arrow), 
EpCAM (Red, to visualise bronchial epithelium) and GFP (ILC2, white arrow). Highlighted in the insets 
(white dashed line) are areas of ILC2 and CD4+ T cell accumulation. (B) Quantification of the number of 
IL-13+GFP+ cells close to large blood vessels versus alveolar capillaries. (C) GFP+ cells were assessed 
for ILC2 phenotypic expression by flow cytometry. Live GFP+CD45+CD4-Linneg cells co-expressing 
CD90.2, KLRG-1 and intracellular IL-13 (dot plots), with CD127 and CD25 expression depicted as 
histogram plots. (D) Quantification of number of IL-13 producing ILC2 versus CD4 T cells. n = 4 mice per 
group. Data representative of 4 experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 and ****P < 0.0001. 
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Fig. S5. Chemokine receptor expression on ILC, related to Fig 4. Mice were treated with rIL-33 (1µg, 
3 times a week for 1 week) or PBS (25µl) and culled 24h after last dose. Percentage of lung ILC 
(GFP+CD45+LinnegKLRG1+CD127+CD90.2+) expressing chemokine receptors in mice treated with (A) PBS 
or (B) rIL-33. Levels of (C) CCL1 (D) RANTES. (E) CCL8 expression levels in lung epithelial cells, 
endothelial cells, airway macrophages (AM) and non-AM. For panels A and B, n = 4 mice per group. Data 
representative of 4 experiments. For C and D, n = 5 mice (Mock(PBS)) and mice 6 mice (IL-33) per group 
and in E, n= 5 mice per group. Data representative of 2 experiments * P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001. 
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Fig. S6. Phenotype and IL-13 production by human ILC2 lines, related to figure4 and 5. Human 
ILC2 lines were generated.  (A) GATA-3 and IL-13 expression by flow cytometry. (B) IL-13 production by 
ELISA as shown in. ILC2 lines were starved of either, IL-2, IL-7 or IL-33 for 72 hours and phenotype, 
proliferation, cytokine production and motility were compared to ILC2 that received all three cytokines. 
(C) Bright field images following starvation and quantification of viability. (D) GATA-3 and (E) Ki-67 
expression assessed by flow cytometry. (F) IL-5 protein levels by ELISA. (G) track speed. n  ≥  3 donors 
(in triplicate). Data representative of 2 experiments. .∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and,∗∗∗∗ p < 
0.0001. 
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Fig. S7. ILC2 motility on extracellular matrix proteins, collagen-III and proteoglycans Versican and 
tenascin-C, related to figure 5A-C. (A) Human ILC2s seeded on tissue culture plates coated with either 
10% FBS, collagen-III (col-III), versican or tenascin-C and migratory dynamics quantified as track speed. 
(B) GATA-3 expression and (C)IL-5 production from human ILC2 lines grown with either Collagen-I (col-I) 
or Collagen-IV (col-IV). Data shown are representative of 2 experiments with a total of n= 4 donor cell lines 
per treatment performed in triplicate. 
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Fig. S8. BAPN fails to affect ILC2 cytokine production and eosinophil movement, related to figure 
8G. Balb/c mice were treated with rIL-33 or PBS with or without BAPN. (A) Lung ILC2 were FACS sorted 
and seeded on FBS or collagen-I (col-I) in the presence or absence of BAPN or CCL8 and IL-5 production 
was assessed by ELISA. Live PCLS were obtained and imaged for eosinophils (Siglec-F+CD11c-) and 
motility was quantified by (B) track length and (C) track speed. n = 4 mice per group. Data representative 
of 2 experiments. 
 
